The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

Multiple myeloma in the marrow: pathogenesis and treatments

(2016) Heather Fairfield et al.   Annals of the New York Academy of Sciences

Advances in the pathogenesis and diagnosis of multiple myeloma

(2015) M. Chesi et al.   International Journal of Laboratory Hematology

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma

(2015) Enrica Borsi et al.   Translational Research

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

(2015) Rikio Suzuki et al.   PLoS One

The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells

(2014) Bettina Grötsch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1)

(2014) Na Ye et al.   JOURNAL OF MEDICINAL CHEMISTRY

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

(2013) Z. Tian et al.   BLOOD

Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128–350 triggers MM cell death via c-Jun upregulation

(2013) Fengjuan Fan et al.   CANCER LETTERS

HIF-1  of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target

(2013) R. Ria et al.   CLINICAL CANCER RESEARCH

Targeting transcription factors

(2013) Jennifer E. Yeh et al.   CURRENT OPINION IN ONCOLOGY

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

The role of tumour–stromal interactions in modifying drug response: challenges and opportunities

(2013) Douglas W. McMillin et al.   NATURE REVIEWS DRUG DISCOVERY

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease

(2013) L Lodé et al.   Blood Cancer Journal

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

The diverse roles of IRF4 in late germinal center B-cell differentiation

(2012) Nilushi S. De Silva et al.   IMMUNOLOGICAL REVIEWS

Ets-1 Activates Overexpression of JunB and CD30 in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

(2011) Mariko Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

(2011) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma

(2011) T Kanno et al.   ONCOGENE

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

(2010) C. M. Annunziata et al.   BLOOD

Novel functions for NFκB: inhibition of bone formation

(2010) Susan A. Krum et al.   Nature Reviews Rheumatology

A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect

(2009) Luca Agnelli et al.   GENES CHROMOSOMES & CANCER

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA